Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27305897 | 0.89 | ELANE (0.52) | RAB9AMAPTL3MBTL1ALDH1A1ELANE | |
| SCHEMBL3736517 | 0.88 | ALDH1A1 (0.53) | RAB9AMAPTALDH1A1HTTNPC1 | |
| SCHEMBL8636288 | 0.86 | ALDH1A1 (0.54) | RAB9AMAPTALDH1A1HTTNPC1 | |
| SCHEMBL19872027 | 0.85 | ALDH1A1 (0.50) | RAB9AALDH1A1HTTNPC1POLB | |
| SCHEMBL3731737 | 0.85 | ALDH1A1 (0.50) | RAB9AMAPTALDH1A1HTTNPC1 | |
| SCHEMBL18400889 | 0.85 | MIF (0.47) | RAB9AMAPTL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL18074587 | 0.84 | ELANE (0.50) | RAB9AMAPTL3MBTL1ALDH1A1ELANE | |
| SCHEMBL10551219 | 0.84 | ALDH1A1 (0.53) | RAB9AMAPTALDH1A1HTTNPC1 | |
| SCHEMBL27339923 | 0.83 | ALDH1A1 (0.49) | RAB9AMAPTALDH1A1HTTNPC1 | |
| SCHEMBL7175493 | 0.83 | ALDH1A1 (0.52) | RAB9AMAPTL3MBTL1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109476642-B | Compounds and their use for reducing uric acid levels | 阿奎斯特有限责任公司 | 2022-01-25 | — | — | CN | disclosed |
| US-10011603-B2 | Process for preparing a carbapenem antibiotic | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-07-03 | — | — | US | disclosed |
| US-10011603-B2 | Process for preparing a carbapenem antibiotic | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-07-03 | — | — | US | disclosed |
| US-20170210744-A1 | PROCESS FOR PREPARING A CARBAPENEM ANTIBIOTIC | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-07-27 | — | — | US | disclosed |
| US-20170210744-A1 | PROCESS FOR PREPARING A CARBAPENEM ANTIBIOTIC | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-07-27 | — | — | US | disclosed |
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-7645786-B2 | 1-aryl-4-cyclopropylpyrazoles with at least one fluorine attached to the cyclopropyl ring; parasiticides; fleas; extended duration of action for at least 28 days | PFIZER INC. (US) | 2010-01-12 | — | — | US | disclosed |
| WO-2008072053-A2 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2008-06-19 | — | — | WO | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| US-20030186924-A1 | Prodrugs | MEDIVIR AB | 2003-10-02 | — | — | US | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
| US-20020128301-A1 | Non-nucleoside reverse transcriptase inhibitors | AB, Medivir (SE) | 2002-09-12 | — | — | US | disclosed |
| EP-1150956-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2001-11-07 | — | — | EP | disclosed |
| EP-1121366-A1 | PRODRUGS OF PHOSPHOROUS-CONTAINING PHARMACEUTICALS | MEDIVIR AB (SE) | 2001-08-08 | — | — | EP | disclosed |
| EP-1054891-A1 | PRODRUGS | MEDIVIR AB (SE) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000047561-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| WO-1999051613-A1 | PRODRUGS OF PHOSPHOROUS-CONTAINING PHARMACEUTICALS | MEDIVIR AB (SE) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999041275-A1 | PRODRUGS | MEDIVIR AB (SE) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011603-B2 | Process for preparing a carbapenem antibiotic | MGAM, HAMP, MB | RAB9A 1404/4885MAPT 3944/4885L3MBTL1 3572/4885 |
| US-20030186924-A1 | Prodrugs | HAVCR2, CYP7A1, IGSF11 | RAB9A 1881/4885MAPT 3289/4885L3MBTL1 2163/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | RAB9A 1697/4885MAPT 4482/4885L3MBTL1 3294/4885 |
| US-20170210744-A1 | PROCESS FOR PREPARING A CARBAPENEM ANTIBIOTIC | MGAM, HAMP, MB | RAB9A 1404/4885MAPT 3944/4885L3MBTL1 3572/4885 |
| US-20020128301-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, CBR1, GAR1 | RAB9A 4637/4885MAPT 3949/4885L3MBTL1 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.